Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.11 USD | +6.02% | +4.07% | +1.79% |
Financials (USD)
Sales 2024 * | 9.68M | Sales 2025 * | 84.68M | Capitalization | 3.46B |
---|---|---|---|---|---|
Net income 2024 * | -459M | Net income 2025 * | -305M | EV / Sales 2024 * | 357 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 40.9 x |
P/E ratio 2024 * |
-7.51
x | P/E ratio 2025 * |
-11.4
x | Employees | 628 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.33% |
Latest transcript on ImmunityBio, Inc.
1 day | +6.02% | ||
1 week | +4.07% | ||
Current month | -4.84% | ||
1 month | -6.07% | ||
3 months | +54.85% | ||
6 months | +223.42% | ||
Current year | +1.79% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 55 | 20-09-30 |
Founder | 71 | 14-11-30 | |
David Sachs
DFI | Director of Finance/CFO | 46 | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 71 | 14-11-30 | |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 19-05-31 |
Wesley Clark
BRD | Director/Board Member | 78 | 21-02-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 5.11 | +6.02% | 8,556,026 |
24-04-24 | 4.82 | -12.20% | 7,938,366 |
24-04-23 | 5.49 | +11.13% | 30,697,001 |
24-04-22 | 4.94 | -6.26% | 5,468,509 |
24-04-19 | 5.27 | +7.33% | 4,571,786 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.79% | 3.46B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.61% | 22.02B | |
-17.84% | 20.9B | |
-9.28% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- IBRX Stock